‘The Run Is Worth The Slide:’ FDA Advisors Urge Expansion Of J&J’s CAR-T Carvykti Despite Initial Upfront Treatment Risks

 
• By Sarah Karlin-Smith and Sue Sutter
an older man and woman happily slide down a playground slide
Early treatment risks are outweighed by possibility of prolonged period of durable response, ODAC says of J&J's CAR-T in earlier lines of multiple myeloma treatment. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers